Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Vaccinex, Inc.

2 abstracts

Abstract
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
Org: H. Lee Moffitt Cancer Center and Research Institute, Vaccinex, Inc.,
Abstract
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.
Org: University of Rochester Cancer Center & Wilmot Cancer Institute, Vaccinex, Inc., University of North Carolina at Chapel Hill,